Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma
Trial Timeline
Feb 9, 2017 → Apr 30, 2028
NCT ID
NCT02977780About Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115
Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115 is a phase 2 stage product being developed by Eli Lilly for Glioblastoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02977780. Target conditions include Glioblastoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02977780 | Phase 2 | Recruiting |
Competing Products
20 competing products in Glioblastoma